Yes, Donald Trump has been diagnosed with coronary artery disease. His coronary calcium scores have been tracked since 2009, when a CAC score of 34 indicated mild plaque buildup in his arteries. By 2018, that score had climbed to 133, crossing the threshold of 100 that physicians use to confirm the presence of heart disease with moderate plaque accumulation. He takes Rosuvastatin (Crestor) to manage his cholesterol and a daily 325 mg aspirin for cardiac prevention.
In July 2025, Trump received an additional diagnosis of chronic venous insufficiency after mild swelling was observed in his lower legs. These diagnoses are not uncommon for a man in his late 70s, and the White House has repeatedly characterized Trump’s overall health as “excellent.” But the details embedded in his medical disclosures raise legitimate questions that deserve scrutiny beyond press secretary talking points. A president’s health is a matter of public interest, and the gap between official characterizations and the clinical reality of managing multiple cardiovascular conditions is worth examining closely. This article walks through what we actually know about Trump’s heart disease based on documented medical records and public disclosures, what chronic venous insufficiency means in practical terms, the aspirin dosing controversy, and how the White House has framed these health revelations over the course of 2025 and into 2026.
Table of Contents
- What Exactly Is Trump’s Coronary Artery Disease Diagnosis and How Serious Is It?
- What Does Chronic Venous Insufficiency Mean for a President Over 70?
- The Aspirin Debate — Why Trump’s 325 mg Daily Dose Raises Red Flags
- Reading Between the Lines of Trump’s 2025 Medical Reports
- Cognitive Health Claims and the Limits of Presidential Medical Transparency
- What Chronic Venous Insufficiency Means for Everyday Americans
- What Comes Next — Monitoring a President’s Heart Health in Real Time
- Conclusion
- Frequently Asked Questions
What Exactly Is Trump’s Coronary Artery Disease Diagnosis and How Serious Is It?
Coronary artery disease is the most common type of heart disease in the United States. It develops when plaque — a combination of cholesterol, fat, calcium, and other substances — builds up inside the coronary arteries that supply blood to the heart. Trump’s case has been documented through coronary artery calcium scoring, a CT-based imaging test that quantifies the amount of calcified plaque in those arteries. In 2009, his CAC score was 34, placing him in the range of mild plaque. By 2013 it had nearly tripled to 98, and by 2018 it reached 133. Any score above 100 is considered confirmation of heart disease with moderate plaque buildup, and it generally signals elevated risk for heart attacks and other cardiac events over the following decade. To put this in context, a CAC score of zero means no detectable calcified plaque and is associated with very low short-term cardiac risk.
A score between 1 and 99 suggests mild disease, while 100 to 399 falls into the moderate range. Scores above 400 indicate severe disease. Trump’s 2018 score of 133 placed him in the lower end of the moderate category, which is a meaningful finding but not an emergency. It is, however, the kind of result that typically prompts physicians to intensify preventive treatment. That is precisely what happened: Trump’s physician increased his Rosuvastatin dosage and recommended dietary and exercise changes. The progression from 34 to 133 over nine years is consistent with the natural trajectory of coronary plaque buildup, particularly in older men with Trump’s lifestyle profile. The question independent cardiologists have raised is not whether the disease exists — it clearly does — but whether the preventive regimen is aggressive enough and whether the public is getting a complete picture of its implications.
What Does Chronic Venous Insufficiency Mean for a President Over 70?
On July 17, 2025, white house press secretary Karoline Leavitt announced that trump had been diagnosed with chronic venous insufficiency after he was examined for mild swelling in his lower legs. Diagnostic testing, including vascular studies and a leg ultrasound reviewed by Dr. Sean Barbabella, confirmed the condition. Leavitt described it as a “benign and common condition, particularly in individuals over the age of 70.” Follow-up testing found no evidence of deep vein thrombosis or arterial disease, and an echocardiogram performed at the same time showed normal cardiac structure and function. CVI occurs when the valves in the leg veins do not work properly, causing blood to pool in the lower extremities rather than returning efficiently to the heart. It affects approximately one in 20 adults and becomes increasingly common after age 50. Symptoms can range from mild swelling and discomfort to skin changes, discoloration, and in advanced cases, venous ulcers.
For most people, CVI is managed with compression stockings, leg elevation, exercise, and sometimes medication. It is not typically life-threatening. However, characterizing CVI as purely “benign” risks oversimplifying the clinical picture. In a 79-year-old man who also has documented coronary artery disease and takes a high daily dose of aspirin, CVI introduces additional considerations around circulation, mobility, and medication interactions. The condition can worsen over time if not managed, and any swelling in the lower extremities requires ongoing monitoring to rule out more serious developments like DVT. The fact that initial testing was negative for clotting is reassuring, but CVI is a chronic condition — the word “chronic” is right there in the name. It does not go away; it is managed.
The Aspirin Debate — Why Trump’s 325 mg Daily Dose Raises Red Flags
One of the more notable details in Trump’s medical disclosures is that he takes 325 mg of aspirin daily for cardiac prevention. This is a full-strength dose — four times the 81 mg low-dose aspirin that most cardiologists now recommend for patients who need antiplatelet therapy. The distinction matters because the higher dose significantly increases the risk of gastrointestinal bleeding without providing proportionally better cardiac protection. Major cardiology guidelines in recent years have actually moved away from recommending daily aspirin for primary prevention in many older adults precisely because the bleeding risks can outweigh the cardiac benefits. Trump’s aspirin dose has also been cited as the explanation for visible bruising.
Hand bruising that appeared in photographs during 2025 was attributed by the White House to “frequent handshaking and the use of aspirin.” In a January 2026 interview with the Wall Street Journal, Trump himself dismissed health concerns and attributed visible bruises to his high aspirin dose, saying “My health is perfect.” The bruising explanation is medically plausible — aspirin inhibits platelet function, making blood vessels more prone to visible bruising from minor trauma. But it also illustrates a broader pattern where specific medical details are used to deflect rather than inform. The more relevant question is why Trump’s physicians have kept him on 325 mg rather than the lower dose that carries less bleeding risk. Independent cardiologists, including those quoted by NPR, have flagged this as an unusual choice that warrants explanation. It is the kind of clinical decision that may have sound reasoning behind it, but the public has not been given that reasoning.
Reading Between the Lines of Trump’s 2025 Medical Reports
Trump underwent multiple rounds of medical testing throughout 2025, and the results were released in carefully staged disclosures. In April 2025, a physical that included an EKG and echocardiogram showed no abnormalities, a normal ejection fraction, and normal heart function. White House physician Dr. Sean Barbabella declared Trump in “excellent health.” In October 2025, a follow-up included lab tests — CBC, metabolic panel, coagulation profile, D-dimer, BNP, and cardiac biomarkers — all within normal limits. Trump’s cardiac age was assessed at 65, which is 14 years younger than his biological age of 79 at the time. The “cardiac age” framing is worth unpacking. It is a useful patient communication tool, not a precise medical measurement.
It is typically derived by comparing an individual’s cardiac risk factors and test results against population averages. Telling a patient their heart looks like that of a 65-year-old is encouraging, but it does not erase the documented coronary artery disease or the ongoing need for statin therapy and blood thinners. A 65-year-old cardiac age still puts someone well within the range where heart attacks, strokes, and other cardiovascular events are a real possibility. In December 2025, CT scan results were released showing what the White House described as “perfectly normal” cardiovascular imaging — no arterial narrowing, normal heart chambers, healthy vessel walls, no inflammation or clotting. Notably, Trump later clarified in his January 2026 Wall Street Journal interview that his October visit to Walter Reed included a CT scan of his heart and abdomen, not an MRI as initially reported by some outlets. The distinction between CT and MRI imaging matters technically, and the initial confusion raised questions about transparency. But the corrected record — showing clean CT results — is a legitimately positive finding. The tradeoff with these disclosures is that they are filtered through the White House communications apparatus before reaching the public, making it difficult to evaluate them with the same rigor as an independent medical record review.
Cognitive Health Claims and the Limits of Presidential Medical Transparency
In his January 2026 Wall Street Journal interview, Trump claimed to have passed his “third straight” cognitive test. While the specifics of which cognitive screening tool was used and the exact results have not been disclosed in detail, the claim fits a pattern of using broad superlatives — “perfect,” “excellent,” “fully fit” — that tell the public relatively little about clinical specifics. Cognitive screening tests like the Montreal Cognitive Assessment (MoCA) are designed to detect significant impairment, not to provide a nuanced picture of cognitive function. Passing one is a low bar, not a clean bill of cognitive health. This matters because cardiovascular disease — including the coronary artery disease Trump is managing — is a known risk factor for cognitive decline over time. Reduced blood flow, chronic inflammation, and the cumulative effects of vascular disease can all affect brain function.
This does not mean Trump is cognitively impaired. It means that the intersection of his documented cardiovascular conditions and his age places him in a demographic where regular, transparent cognitive monitoring is warranted. The current approach of periodic claims of perfect health, filtered through press statements, does not meet the standard of transparency that the public interest demands. Presidential medical transparency has always been a fraught topic. There is no legal requirement for presidents to disclose their health records, and the tradition of releasing physician summaries gives enormous discretion to the White House. The tension between patient privacy and public accountability is real, but when a sitting president has documented heart disease and a newly diagnosed circulatory condition, the public deserves more than curated adjectives.
What Chronic Venous Insufficiency Means for Everyday Americans
Trump’s CVI diagnosis put a spotlight on a condition that affects millions of Americans but rarely makes headlines. About one in 20 adults live with some form of chronic venous insufficiency, and the risk increases substantially after age 50. Risk factors include prolonged standing or sitting, obesity, a history of blood clots, family history, and pregnancy.
Many people with mild CVI manage it effectively with lifestyle changes — regular walking, avoiding prolonged standing, elevating the legs, and wearing compression stockings. For those who see their own symptoms reflected in Trump’s diagnosis, the key takeaway is that CVI is worth taking to your doctor even if it seems like “just swelling.” Left unmanaged, it can progress to more serious complications including skin breakdown and venous ulcers. The fact that the White House framed the diagnosis as benign and common is accurate in a general sense, but it should not discourage anyone from seeking evaluation and treatment. Early intervention makes a meaningful difference in long-term outcomes.
What Comes Next — Monitoring a President’s Heart Health in Real Time
Looking ahead, the central question is not whether Trump has heart disease — that is established fact — but whether the management of his conditions will remain effective as he ages in office. Coronary artery disease is progressive. Chronic venous insufficiency is lifelong. Both require ongoing monitoring, medication adjustments, and lifestyle management. The December 2025 CT results showing clean vessel walls are encouraging, suggesting that the statin therapy may be effectively controlling plaque progression.
But one good scan does not end the story. The public should expect continued disclosures, likely timed to coincide with routine physicals, and continued debate about whether those disclosures are sufficiently detailed. Independent medical commentary will remain essential for translating White House health summaries into plain language. And the aspirin dosing question — 325 mg versus 81 mg — is likely to remain a point of contention among cardiologists watching from the outside. The health of any president is ultimately a question of governance, not just medicine, and the American public has a legitimate interest in getting answers that go beyond “excellent” and “perfect.”.
Conclusion
Donald Trump has documented coronary artery disease, confirmed by coronary calcium scores that have risen from 34 in 2009 to 133 in 2018. He was diagnosed with chronic venous insufficiency in July 2025 after swelling appeared in his lower legs. He manages these conditions with Rosuvastatin, a daily 325 mg aspirin — a dose that has drawn scrutiny from independent cardiologists — and ongoing monitoring.
His 2025 test results, including lab work, imaging, and cardiac assessments, have all come back within normal limits, and his cardiac age was assessed at 65. None of this means Trump is in imminent medical danger, and it would be irresponsible to suggest otherwise. But it does mean the president of the United States is managing multiple cardiovascular conditions simultaneously while in office, and the public’s access to the details of that management is filtered through a communications operation with obvious incentives to emphasize the positive. The facts deserve to be laid out plainly — not to alarm, but because informed citizens make better decisions, and a president’s health is everyone’s business.
Frequently Asked Questions
Does Trump actually have heart disease?
Yes. Coronary artery disease has been confirmed through coronary calcium scoring. His 2018 CAC score of 133 exceeds the 100 threshold that indicates the presence of heart disease with moderate plaque buildup.
What is chronic venous insufficiency and is it serious?
CVI is a condition where leg vein valves do not function properly, causing blood to pool in the lower legs. It affects about one in 20 adults and is especially common in people over 70. It is generally manageable but requires ongoing treatment to prevent progression.
Why does Trump take 325 mg of aspirin instead of the standard 81 mg?
The specific reasoning has not been publicly explained by his physicians. Most cardiologists now prefer the 81 mg dose because it provides similar cardiac benefits with significantly lower gastrointestinal bleeding risk. The higher dose has been cited as the cause of Trump’s visible bruising.
What did Trump’s 2025 medical tests show?
His April 2025 physical showed normal EKG and echocardiogram results. October 2025 lab work — including cardiac biomarkers, CBC, and coagulation profiles — was within normal limits, with a cardiac age assessed at 65. December 2025 CT imaging showed no arterial narrowing and normal heart chambers.
Has Trump passed cognitive testing?
Trump claimed in January 2026 to have passed his “third straight” cognitive test. However, the specific test used and detailed results have not been disclosed publicly. Standard cognitive screening tests are designed to detect significant impairment, not to provide a comprehensive assessment of cognitive function.
Is coronary artery disease curable?
No. Coronary artery disease is a chronic, progressive condition. It can be managed with medication, lifestyle changes, and in some cases surgical intervention, but plaque buildup in the arteries cannot be fully reversed. The goal of treatment is to slow progression and reduce the risk of heart attacks and strokes.